In its latest quarterly filing, Merck reported continued growth driven by core products like Keytruda and Gardasil, alongside integration of recent acquisitions Terns Pharmaceuticals and Cidara Therapeutics. Regulatory approvals, including Health Canada’s nod for Keytruda combined with Enfortumab Vedotin, bolster Merck’s oncology portfolio. The company's business model emphasizes R&D-led innovation with collaborations, while facing risks from regulatory costs and patent expirations. Monitoring clinical trial progress and commercialization efficiency will be critical going forward.